UBS Group
CLGN icon

UBS Group’s CollPlant Biotechnologies CLGN Stock Holding History

UBS Group’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51 Buy
+95
New +$96 ﹤0.01% 10201
2025
Q2 		– Sell
-24,074
Closed -$62.1K – 10310
2025
Q1 		$62.1K Buy
24,074
+1,866
+8% +$6.58K ﹤0.01% 7414
2024
Q4 		$79.9K Buy
22,208
+10,261
+86% +$41.7K ﹤0.01% 7009
2024
Q3 		$59.3K Buy
11,947
+4,805
+67% +$23.5K ﹤0.01% 6703
2024
Q2 		$35.5K Buy
7,142
+2,362
+49% +$13.1K ﹤0.01% 6955
2024
Q1 		$25.6K Buy
+4,780
New +$25.8K ﹤0.01% 6806
2023
Q4 		– Sell
-5,690
Closed -$31.7K – 9365
2023
Q3 		$31.7K Sell
5,690
-858
-13% -$5.68K ﹤0.01% 6568
2023
Q2 		$53.4K Sell
6,548
-1,456
-18% -$10.6K ﹤0.01% 6438
2023
Q1 		$56.2K Buy
8,004
+964
+14% +$9.46K ﹤0.01% 6364
2022
Q4 		$58.8K Sell
7,040
-2,126
-23% -$14.5K ﹤0.01% 6606
2022
Q3 		$62K Buy
9,166
+1,652
+22% +$13.4K ﹤0.01% 6134
2022
Q2 		$60K Buy
7,514
+4,085
+119% +$37.5K ﹤0.01% 5777
2022
Q1 		$38K Sell
3,429
-1,837
-35% -$20.2K ﹤0.01% 6753
2021
Q4 		$86K Buy
+5,266
New +$94K ﹤0.01% 6449
2021
Q3 		– Sell
-2,010
Closed -$43K – 9586
2021
Q2 		$43K Buy
2,010
+832
+71% +$13.3K ﹤0.01% 6568
2021
Q1 		$16K Buy
+1,178
New +$17.8K ﹤0.01% 7564
2020
Q4 		– Sell
-273
Closed -$2K – 8417
2020
Q3 		$2K Sell
273
-422
-61% -$3.8K ﹤0.01% 7640
2020
Q2 		$7K Buy
+695
New +$7.16K ﹤0.01% 7213
2019
Q4 		– Sell
-5,304
Closed -$21K – 8127
2019
Q3 		$21K Buy
5,304
+3,521
+197% +$14.2K ﹤0.01% 6704
2019
Q2 		$8K Buy
+1,783
New +$9.36K ﹤0.01% 7177
2019
Q1 		– Sell
-3,316
Closed -$14K – 7765
2018
Q4 		$14K Sell
3,316
-6,515
-66% -$34K ﹤0.01% 7031
2018
Q3 		$50K Buy
+9,831
New +$54.2K ﹤0.01% 6160

Other funds holding CLGN

SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LWMI
Legacy Wealth Management (Idaho) Boise, Idaho $201M AUM 259.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

UBS Group's CLGN Position: Q1 2026 in Review

UBS Group opened a new position in CollPlant Biotechnologies (CLGN) in Q1 2026: 95 shares worth $51. The stake represents ﹤0.01% of the portfolio and ranks #10201 among its holdings. This is a return to the name: UBS Group previously reported a position in CLGN as recently as Q1 2025.

UBS Group first reported a position in CLGN in Q3 2018 and has held it in 22 quarters since. The position peaked at $86K in Q4 2021. 21 funds tracked by Wall St. Rank hold CLGN as of Q1 2026.

  • UBS Group held 95 shares of CollPlant Biotechnologies worth $51 as of Q1 2026.
  • CollPlant Biotechnologies was a new UBS Group position in Q1 2026.
  • CollPlant Biotechnologies made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10201 holding.
  • UBS Group first reported a position in CollPlant Biotechnologies in Q3 2018 and has held it in 22 quarters since.
  • UBS Group's CollPlant Biotechnologies position peaked at $86K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.